These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 26616595)

  • 21. Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
    Charbonnel B; Schweizer A; Dejager S
    Hosp Pract (1995); 2013 Apr; 41(2):93-107. PubMed ID: 23680741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review.
    Frandsen CS; Madsbad S
    Diabet Med; 2014 Nov; 31(11):1293-300. PubMed ID: 25112609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety assessment of basal supported oral therapy (BOT) with insulin glargine in a real-life clinical setting, stratified by concomitant orally administered antidiabetic agent (OAD) regimens including dipeptidyl peptidase-4 inhibitor (DPP-4i): subanalysis of the ALOHA2 study, drug-use surveillance in Japan.
    Tsukube S; Kadowaki T; Odawara M
    Diabetol Int; 2016 Sep; 7(3):299-307. PubMed ID: 30603277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dipeptidyl peptidase-4 inhibitors as a third-line oral antihyperglycaemic agent in patients with type 2 diabetes mellitus: the impact of ethnicity.
    Zhang X; Brooks B; Molyneaux L; Landy E; Banatwalla R; Wu T; Wong J; Su B; Yue DK
    Int J Endocrinol; 2014; 2014():354040. PubMed ID: 25180036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment progression in sulfonylurea and dipeptidyl peptidase-4 inhibitor cohorts of type 2 diabetes patients on metformin.
    Peng X; Jiang D; Liu D; Varnado OJ; Bae JP
    Patient Prefer Adherence; 2016; 10():1539-46. PubMed ID: 27570448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in Japan.
    Odawara M; Sagara R
    J Diabetes Metab Disord; 2015; 15():21. PubMed ID: 27382546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Choice of Treatment Regimen as Add-On to Insulin in Japanese Patients with Type 2 Diabetes Mellitus: Physicians' Perspective in a Real-World Setting, Insight from a Web Survey.
    Imai K; Murayama H; Hirose T
    Diabetes Ther; 2018 Oct; 9(5):1869-1881. PubMed ID: 30058059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term Effects of Mitiglinide in Japanese Diabetics Inadequately Controlled with DPP-4 Inhibitor or Biguanide Monotherapy.
    Kaku K; Inagaki N; Kobayashi N
    Diabetes Ther; 2014 Jun; 5(1):97-111. PubMed ID: 24488695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Saxagliptin for type 2 diabetes.
    Chacra AR
    Diabetes Metab Syndr Obes; 2010 Sep; 3():325-35. PubMed ID: 21437102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Effects of Metformin and Dipeptidyl Peptidase-4 Inhibitors in Japanese Obese Patients with Type 2 Diabetes: A Claims Database Study.
    Odawara M; Aoi S; Takeshima T; Iwasaki K
    Diabetes Ther; 2021 Aug; 12(8):2165-2177. PubMed ID: 34218420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus.
    Yagi S; Aihara K; Akaike M; Fukuda D; Salim HM; Ishida M; Matsuura T; Ise T; Yamaguchi K; Iwase T; Yamada H; Soeki T; Wakatsuki T; Shimabukuro M; Matsumoto T; Sata M
    Diabetes Metab J; 2015 Aug; 39(4):342-7. PubMed ID: 26301197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus.
    Kim SA; Shim WH; Lee EH; Lee YM; Beom SH; Kim ES; Yoo JS; Nam JS; Cho MH; Park JS; Ahn CW; Kim KR
    Diabetes Metab J; 2011 Apr; 35(2):159-65. PubMed ID: 21738898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship Between Duration of Type 2 Diabetes and Effectiveness of DPP-4 Inhibitor Versus Sulfonylurea as Add-on Therapy: A Post Hoc Analysis.
    Brath H; Paldánius PM; Bader G; Mathieu C
    Diabetes Ther; 2017 Aug; 8(4):829-836. PubMed ID: 28631242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-interventional, Single-Arm, Open-Label, Multicenter Observational Study.
    Kim SY; Kim S
    Diabetes Ther; 2023 Jan; 14(1):109-121. PubMed ID: 36417158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus.
    Cho HA; Jung YL; Lee YH; Lee YC; Lee JE; Lee SJ; Jeong SJ; Kim CH
    J Obes Metab Syndr; 2017 Jun; 26(2):107-113. PubMed ID: 31089504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dipeptidyl peptidase-4 inhibitors are effective in Japanese type 2 diabetic patients with sustained endogenous insulin-secreting capacity, a higher body mass index and insulin resistance.
    Kozawa J; Kitamura T; Nishizawa H; Yasuda T; Maeda N; Otsuki M; Okita K; Iwahashi H; Kaneto H; Funahashi T; Imagawa A; Shimomura I
    J Diabetes Investig; 2013 Mar; 4(2):190-4. PubMed ID: 24843651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F).
    Terawaki Y; Iwaya C; Nomiyama T; Shimono D; Horikawa T; Fujimura-Tanaka Y; Shigeoka T; Hamanoue N; Motonaga R; Tanabe M; Yanase T; Kawanami D;
    Diabetol Int; 2020 Jul; 11(3):274-282. PubMed ID: 32802709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electronic medical records-based comparison of glycemic control efficacy between sulfonylureas and dipeptidyl peptidase-4 inhibitors added on to metformin monotherapy in patients with type 2 diabetes.
    Lee S; Lee S; Jang IJ; Yu KS; Rhee SJ
    Transl Clin Pharmacol; 2020 Dec; 28(4):199-207. PubMed ID: 33425803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in spanish patients.
    Sicras-Mainar A; Navarro-Artieda R
    Diabetes Metab J; 2015 Feb; 39(1):74-81. PubMed ID: 25729716
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.